Sickle cell disease—the subject of a new Seminar in The Lancet—is one of the most prevalent and fastest-growing genetic disorders worldwide. Although its true prevalence is difficult to determine ...

You are enjoying a warm summer evening outdoors, and you feel the familiar, itchy pinch of a mosquito bite.

A dual-action HIV antibody–drug conjugate forces Env to open, then blocks it, boosting virus neutralization up to tenfold in the lab.

Digital literacy meets HIV awareness through Empower+ By Staff Writer, ITWebJohannesburg, 10 Mar 2026Empower+ equips adolescent girls with foundational and AI skills, preparing them for an AI-enabled ...

Assistant Minister for Health Penioni Ravunawa says the rise in HIV cases in Fiji remains a major challenge for the Ministry of Health. In the first six months of 2025 alone, 1,226 new HIV cases were ...

Guest coach Joanne Morgan has praised the potential within the Fiji Pearls squad after spending two days working closely with ...

Researchers at Queen Mary University of London have led the clinical development of the first non-integrase strand-transfer inhibitor (INSTI) single tablet treatment for HIV, among growing concern for ...

More than 30 million people with HIV must take antiretroviral therapy (ART) medications daily to keep the virus under control, according to the Joint United Nations Programme on HIV/AIDS (UNAIDS). The ...

Nearly 45 years after the first HIV diagnosis, science is closer than ever to a cure for the virus that causes AIDS — but we’re not there yet, researchers say. While perhaps a dozen people worldwide ...

Medications have kept Tori Samuel’s HIV at bay for decades. The part-time worker from Ocala, Florida, has thrived, marrying her husband and giving birth to three children, none of whom have the virus.

Though Gilead Sciences made waves last June with a landmark FDA approval for its twice-yearly HIV preventive Yeztugo (lenacapavir), the first-in-class drug had previously been used as a long-acting ...

Dec 15 (Reuters) - Gilead Sciences (GILD.O), opens new tab said on Monday its experimental HIV treatment was found to be statistically non-inferior to its top-selling drug Biktarvy in a late-stage ...